Trial Profile
Non-Inferiority of GSK Biologicals' Meningococcal Vaccine (GSK134612) Compared to Licensed MenC-CRM197 Conjugate Vaccine in Healthy Children.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Acronyms MenACWY-TT-081 PRI
- Sponsors GlaxoSmithKline; GSK
- 02 May 2019 This trial has been completed in France according to European Clinical Trials record.
- 28 Oct 2011 Planned end date changed from Mar 2014 to May 2014 as reported by ClinicalTrials.gov.
- 23 Dec 2010 Status changed from completed to not yet recruiting as reported by ClinicalTrials.gov. (NCT01266993).